James J. Gibbons

Publications by Year

Research Areas

Chemical and Physical Properties in Aqueous Solutions, PI3K/AKT/mTOR signaling in cancer, Lung Cancer Treatments and Mutations, Cancer therapeutics and mechanisms, Thermodynamic properties of mixtures

Most-Cited Works

• → Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR(2001)973 cited
• SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.(2003)
• → Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin(2009)326 cited
• → The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy(2007)242 cited
• → Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor(2010)211 cited
• → Synthesis and SAR of [1,2,4]Triazolo[1,5-a]pyrimidines, a Class of Anticancer Agents with a Unique Mechanism of Tubulin Inhibition(2006)209 cited
• → Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2(2010)208 cited
• → Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth(2009)208 cited
• → Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study(2018)188 cited
• → Targeting mTOR globally in cancer: Thinking beyond rapamycin(2009)155 cited